NCT05606536 The Impact of Intra-operative Fluid Infusion Rate on Microcirculation
| NCT ID | NCT05606536 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Hradec Kralove |
| Condition | Fluid Therapy |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2022-10-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2022-10-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Intraoperative fluid therapy (IFT) is an integral part of anesthesia care during surgery. Its main indication is the optimization of oxygen supply to the tissues. For elective surgery that is not associated with higher blood loss and a long period of preoperative fasting, including fluids IFT is dosed to cover the basal daily need for fluids. However, it is not clear whether this fluid dose is optimal. Surgery is a stress factor that leads, among other things, to damage of the endothelial glycocalyx (EG). EG binds a significant amount of plasma, which is released during EG destruction and causes relative hemodilution. Isovolumic hemodilution is an established intraoperative procedure that serves to better control bleeding in procedures where bleeding is expected. However, partial hemodilution occurs even with standard IFT, and even when fluids are hardly given at all. Flow parameters in microcirculation have not yet been described depending on IFT conduction. The parameters of the microcirculation reflect its functioning, which will consequently affect the postoperative phase of the patient's moaning and clinical outcome.
Eligibility Criteria
Inclusion Criteria: * elective recumbent and laparoscopic surgery * informed consent Exclusion Criteria: * blood loss over 250 ml * hemodynamic instability requiring noradrenaline infusion
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05606536 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Fluid Therapy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05606536 currently recruiting?
Yes, NCT05606536 is actively recruiting participants. Contact the research team at david.astapenko@fnhk.cz for enrollment information.
Where is the NCT05606536 trial being conducted?
This trial is being conducted at Hradec Králové, Czechia.
Who is sponsoring the NCT05606536 clinical trial?
NCT05606536 is sponsored by University Hospital Hradec Kralove. The trial plans to enroll 80 participants.